US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

por Echols, Roger M, Nagata, Tsutae
Publicado 2021

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance

por Echols, Roger, Ariyasu, Mari, Nagata, Tsutae Den
Publicado 2019

LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority S...

por Wunderink, Richard G, Wunderink, Richard G, Matsunaga, Yuko, Ari, Mari, Ariyasu, Mari, Echols, Roger, Echols, Roger, Menon, Anju, Den Nagata, Tsutae, Den Nagata, Tsutae
Publicado 2019

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)

por Cai, Bin, Echols, Roger, Rudin, Deborah, Morgan, Gareth, Nagata, Tsutae
Publicado 2018

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study

por Portsmouth, Simon, Toyoizumi, Kiichiro, Den Nagata, Tsutae, Tillotson, Glenn S, Echols, Roger
Publicado 2019

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation

por Portsmouth, Simon, Echols, Roger, Toyoizumi, Kiichiro, Tillotson, Glenn, Nagata, Tsutae Den
Publicado 2021

1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies

por Takemura, Miki, Yamano, Yoshinori, Matsunaga, Yuko, Ariyasu, Mari, Echols, Roger, Den Nagata, Tsutae
Publicado 2020

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study

por Portsmouth, Simon, Echols, Roger, Machida, Mitsuaki, Camilo Arjona Ferreira, Juan, Ariyasu, Mari, Den Nagata, Tsutae
Publicado 2019

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program

por Satlin, Michael J., Simner, Patricia J., Slover, Christine M., Yamano, Yoshinori, Nagata, Tsutae D., Portsmouth, Simon
Publicado 2023

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study

por Matsunaga, Yuko, Ariyasu, Mari, Takemura, Miki, Yamano, Yoshinori, Toyoizumi, Kiichiro, Kinoshita, Masahiro, Echols, Roger, Den Nagata, Tsutae
Publicado 2020

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized,...

por Bassetti, Matteo, Ariyasu, Mari, Binkowitz, Bruce, Nagata, Tsutae Den, Echols, Roger M, Matsunaga, Yuko, Toyoizumi, Kiichiro, Doi, Yohei
Publicado 2019

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections

por Matsunaga, Yuko, Sonoyama, Takuhiro, Casanova, Luis, Nagata, Tsutae Den, Echols, Roger, De Gregorio, Fabio, Ogura, Eriko, Portsmouth, Simon
Publicado 2020

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

por Cai, Bin, Echols, Roger, Magee, Glenn, Arjona Ferreira, Juan Camilo, Morgan, Gareth, Ariyasu, Mari, Sawada, Takuko, Nagata, Tsutae “Den”
Publicado 2017

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Path...

por Bassetti, Matteo, Echols, Roger, Matsunaga, Yuko, Portsmouth, Simon, Ariyasu, Mari, Toyoizumi, Kiichiro, Doi, Yohei, Doi, Yohei, Den Nagata, Tsutae
Publicado 2020

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients

por Katsube, Takayuki, Kawaguchi, Nao, Matsunaga, Yuko, Ariyasu, Mari, Den Nagata, Tsutae, Portsmouth, Simon, Paterson, David, Paterson, David, Satlin, Michael J, Zeitlinger, Markus, Echols, Roger, Wajima, Toshihiro
Publicado 2020

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

por Edgeworth, Jonathan D, Merante, Domenico, Patel, Sanjay, Young, Christopher, Jones, Paul, Vithlani, Seema, Wyncoll, Duncan, Roberts, Peter, Jones, Andrew, Den Nagata, Tsutae, Ariyasu, Mari, Livermore, David M, Beale, Richard
Publicado 2019

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)

por Peck‐Radosavljevic, Markus, Simon, Krzysztof, Iacobellis, Angelo, Hassanein, Tarek, Kayali, Zeid, Tran, Albert, Makara, Mihaly, Ben Ari, Ziv, Braun, Marius, Mitrut, Paul, Yang, Sheng‐Shun, Akdogan, Meral, Pirisi, Mario, Duggal, Ajay, Ochiai, Toshimitsu, Motomiya, Tomoko, Kano, Takeshi, Nagata, Tsutae, Afdhal, Nezam
Publicado 2019